TSO3 — Investor Presentation (May 2019)
19 slides from TSO3's investor presentation, May 2019
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | May 2019 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks
Slide 3: Vision. Purpose.
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Patient 3
Slide 4: One Disruptive Technology – Two Large Markets
One Disruptive Technology – Two Large Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Gastrointestinal Supply Department Process/ U.S. ~10,000 Hospitals & Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospitals2 >5
Slide 5: Breakthrough Technologies / Patents
Breakthrough Technologies /// 201 Patents + Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Condensation Layer Dynamic Sterilant De
Slide 6: Value of a Customer - Long Term Model
Value of a Customer - Long Term Model Potential Revenue Per US Customer* (Assuming 2 units, 10 Yr Product Life) “Razor” Capital Equipment Sales $200k-$300k 1-4 units per facility Approx. $0.9m-$1.2m Higher-Margin Revenue Proprietary Consumables $20k-$30k/Sterilizer/Year Opportunity per Customer* “Ra
Slide 7: Proven Value Proposition
Proven Value Proposition* New Metric: Cost per Instrument Sterilized, not Cost per Cycle Competition STERIZONE® VP4 Sterilizer Saves up to 50% in Operating Costs 2 STERIZONE® VP4 Sterilizers = 3+ of the Competition in Throughput One of the Least Expensive Options In the Market Today * Actual custome
Slide 8: Disruptive Technology for OR Support
Disruptive Technology for OR Support The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. Features Advantages Benefits • Dual Chemistry • Simple Single Cycle • Lowest Cost per Instrument Operation Sterilized •
Slide 9: Proven Value Proposition – Independent of Customer Size
Proven Value Proposition – Independent of Customer Size Fewer Cycles Fewer Sterilizers Better Efficiency “STERIZONE® VP4 50% less cost per “We had 4 [competitor] Sterilizers, now STERIZONE® VP4 Sterilizer is 3 times instrument sterilized than we have 2 STERIZONE® VP4 Sterilizers.” more efficient tha
Slide 10: Commercialization Approach - CSSD
Commercialization Approach - CSSD LEVERAGE EARLY INCREASE MARKET ESTABLISH STRONG SUPPORT WITH DIRECT ADOPTERS AWARENESS CUSTOMER SALES, CLINICAL AND TARGETING METRICS TECHNICAL PERSONNEL • Name-brand user- • >5,000 Targeted Customers • High Use Facilities • Trained in-house Personnel base and refer
Slide 11: Sales and Marketing Activity
Sales and Marketing Activity • Sell Direct to End Users 10 Sales Representatives ~5,000 accounts >110 Units Sold Signed Partners/Agents targeted • GPO and IDN Contracts and System Sales 75 Units Installed 450+ • Strategic Pricing: Lower ASPs for Speed opportunities > 30 Units Sold in Last Six Mo
Slide 12: Endoscopy Sterilization – A Greenfield Opportunity
Endoscopy Sterilization – A Greenfield Opportunity Established Base Business Emerging Opportunity Operating Room & Central Sterile Process/ Gastrointestinal Supply Department U.S. ~10,000 Hospitals and Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospit
Slide 13: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Decades old processes with only incremental improvement “Despite reprocessing in accordance with US guidelines, viable microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ens
Slide 14: How Shifts Happen
How Shifts Happen Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction = Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 14
Slide 15: TSO3 Obtains Expanded Endoscope Clearances
TSO3 Obtains Expanded Endoscope Clearances May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4 Sterilizer • Hospitals can terminally sterilize gastrointestinal endoscopes within the cleared intended
Slide 16: Recent Customer Activity
Recent Customer Activity Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization Technology June 15, 2018 - “Being the inaugural facility to offer terminal sterilization of endoscopes using the TSO3 technology, provides our patients with a level of safety above curr
Slide 17: Summary
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model SUMMARY First-to-Market FDA-cleared Device for Terminal Sterilization of Colonoscopes, Duodenoscopes and Gastroscopes (see claims) Direct Commercialization Strategy Growing Installation Base TSX:TOS 17
Slide 18: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (At May 3, 2019 close) $0.32 52 Week High - Low $1.15 - $0.28 Shares Outstanding (May 3, 2019) 93,465,238 Average Daily Volume (50 days) 132.17 k Market Capitalization $29.9 M Institutional Holdings ≈ 15% Total Revenue -
Slide 19: T Sh,
T Sh,